Payment overview · 2025
General Payments
$96.24
4 reported records · 4 companies
Healthcare provider profile · identity verified
Charles M Platz, MD
Allopathic & Osteopathic Physicians|Family Medicine · INDIANAPOLIS, IN · NPI 1790758589
Verified facts
What the public records show
CMS Open Payments records show Charles M Platz, MD received $96.24 in general payments during 2025 across 4 reported records.
Insulet Corporation accounted for 27.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Insulet Corporation | Unresolved — no canonical attribution shown | $26.28 | 27.3% | 1 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $25.49 | 26.5% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$23.83 | 24.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.64 | 21.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $96.24 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $26.28 | 1 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $25.49 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $23.83 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.64 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 123 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
123 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 482 | 135 |
| Amlodipine Besylate | Amlodipine Besylate | 429 | 118 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 358 | 74 |
| Lisinopril | Lisinopril | 285 | 79 |
| Gabapentin | Gabapentin | 282 | 76 |
| Omeprazole | Omeprazole | 249 | 74 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 232 | 28 |
| Levothyroxine Sodium | Levothyroxine Sodium | 226 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 221 | 68 |
| Losartan Potassium | Losartan Potassium | 213 | 60 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 174 | 54 |
| Fluticasone Propionate | Fluticasone Propionate | 164 | 60 |
| Furosemide | Furosemide | 162 | 54 |
| Metformin Hcl Er | Metformin Hcl | 159 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 151 | 45 |
| Bupropion Xl | Bupropion Hcl | 149 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 147 | 49 |
| Duloxetine Hcl | Duloxetine Hcl | 140 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 129 | 35 |
| Simvastatin | Simvastatin | 129 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 128 | 35 |
| Ozempic | Semaglutide | 123 | 28 |
| Alprazolam | Alprazolam | 118 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 116 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 112 | 31 |
| Tramadol Hcl | Tramadol Hcl | 112 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 100 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 97 | 24 |
| Allopurinol | Allopurinol | 94 | 25 |
| Pregabalin | Pregabalin | 94 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 91 | 27 |
| Montelukast Sodium | Montelukast Sodium | 91 | 31 |
| Potassium Chloride | Potassium Chloride | 86 | 20 |
| Famotidine | Famotidine | 85 | 28 |
| Trazodone Hcl | Trazodone Hcl | 84 | 18 |
| Metformin Hcl | Metformin Hcl | 82 | 23 |
| Prednisone | Prednisone | 80 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 78 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 77 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 76 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 71 | 20 |
| Diazepam | Diazepam | 69 | 15 |
| Lovastatin | Lovastatin | 69 | 20 |
| Sertraline Hcl | Sertraline Hcl | 69 | 15 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 68 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 64 | 16 |
| Atenolol | Atenolol | 59 | 17 |
| Glipizide Er | Glipizide | 59 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 58 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 58 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 19 |
| Mounjaro | Tirzepatide | 56 | 14 |
| Propranolol Hcl Er | Propranolol Hcl | 54 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 53 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 53 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 53 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 53 | 12 |
| Carvedilol | Carvedilol | 51 | 19 |
| Clonidine Hcl | Clonidine Hcl | 49 | 13 |
| Cephalexin | Cephalexin | 48 | 32 |
| Eliquis | Apixaban | 48 | 14 |
| Buspirone Hcl | Buspirone Hcl | 47 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 47 | 15 |
| Azelastine Hcl | Azelastine Hcl | 46 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 45 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | suppressed |
| Celecoxib | Celecoxib | 42 | 13 |
| Nifedipine Er | Nifedipine | 42 | suppressed |
| Spironolactone | Spironolactone | 42 | 14 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 41 | 41 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 41 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | 12 |
| Clonazepam | Clonazepam | 40 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 40 | suppressed |
| Jardiance | Empagliflozin | 39 | 12 |
| Meloxicam | Meloxicam | 39 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 39 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 38 | 27 |
| Mirtazapine | Mirtazapine | 38 | suppressed |
| Telmisartan | Telmisartan | 37 | 14 |
| Ibuprofen | Ibuprofen | 36 | 12 |
| Valsartan | Valsartan | 36 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 35 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 34 | 11 |
| Ezetimibe | Ezetimibe | 33 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 27 |
| Estradiol | Estradiol | 32 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Glipizide | Glipizide | 32 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Glimepiride | Glimepiride | 31 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 29 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 28 | suppressed |
| Finasteride | Finasteride | 28 | suppressed |
| Irbesartan | Irbesartan | 28 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | 15 |
| Buprenorphine Hcl | Buprenorphine Hcl | 27 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 27 | 20 |
| Acyclovir | Acyclovir | 25 | suppressed |
| Lidocaine | Lidocaine | 25 | 11 |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Temazepam | Temazepam | 25 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 24 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 24 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 14 |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Klor-Con M20 | Potassium Chloride | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | 14 |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Nabumetone | Nabumetone | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 14 |
| Latanoprost | Latanoprost | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Oxycontin | Oxycodone Hcl | 15 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Methadone Hcl | Methadone Hcl | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Xtampza Er | Oxycodone Myristate | 13 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Tadalafil | Tadalafil | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $96.24 · 4 records | Insulet Corporation | MINIMED 780G, Omnipod, Ozempic, Rybelsus, t:slim X2 Insulin Pump with Control-IQ | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error